SAN FRANCISCO, Oct. 29 – Celera Genomics will include GeneFormatics’ structural proteomics database in its Discovery System, the companies announced Monday.
San Diego, Calif.-based GeneFormatics’ Proteomics Database contains approximately 7,000 novel biochemical function and structure assignments for potential drug targets in humans, according to the company.
Financial details of the agreement were not disclosed.
“Knowledge of the biochemical function and structures of encoded proteins are critical to leveraging the value of genomic data in structure-based drug design processes,” John Chiplin, CEO of GeneFormatics, said in a statement.
Earlier in the month, GeneFormatics raised $22 million in its third round of financing.